Chardan Capital Markets analyst Keay Nakae raised the price target on Emergent BioSolutions (NYSE: EBS) to $71.00 (from $66.00) while maintaining a Buy rating.

The analyst commented, "We believe that the two recently announced acquisitions check a number of boxes that support he Company's long term growth strategy, and allows it to achieve its aspirational goal of reaching $1 billion in annual revenue one year early in 2019. In the near term we do see risk associated with the timing and financial details of the new long term supply agreement for ACAM2000, but believe that the Company will remain the preferred provider of this medical counter measure for the SNS."